Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval.

ABSTRACT:

SUBMITTER: Shahzad M 

PROVIDER: S-EPMC8524351 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature